20-F: ALR Technologies SG Ltd. Files 20-F Annual Report, Citing Going Concern Uncertainty

ALR Technologies SG Ltd. reports recurring losses and uncertainties about raising additional funding, raising substantial doubt about its ability to continue as a going concern.

Summary

• ALR Technologies SG Ltd. has filed its annual report on Form 20-F.
• The company acknowledges substantial doubt about its ability to continue as a going concern due to recurring losses and the need for additional funding.
• The company experienced net losses of $7.47 million in 2023, $10.62 million in 2022, and $8.44 million in 2021.
• The company's accumulated deficit stood at $120.11 million as of December 31, 2023.
• The company's strategy to improve financial condition includes increasing revenues, expanding sales, forming strategic arrangements, and reducing expenses.
• The company's success depends on securing relationships with third-party distributors for its Diabetes Solution and GluCurve products.
• The company faces competition from other companies, many of which have substantially greater resources.
• The company's ordinary shares are quoted on the OTCQB tier of the OTC Markets Group, and failure to meet continued eligibility standards could result in delisting.
• The company's Chairman and CEO, Sidney Chan, and his affiliates own in excess of 60% of the company's outstanding ordinary shares.
• The company is organized under the laws of the Republic of Singapore, which may present challenges for shareholders protecting their interests compared to U.S. corporations.
• The company may be classified as a Passive Foreign Investment Company (PFIC), which could result in adverse U.S. federal income tax consequences to U.S. Holders of the company's ordinary shares.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with recurring losses and doubts about the company's ability to continue as a going concern. While there are some positive aspects, the overall tone is negative due to the significant financial challenges and risks.

Positives

• The company is actively seeking to commence revenue-generating activities for its Diabetes Solution product.
• The company is focused on offering its Diabetes Solution product with cost-effective CGM devices.
• The company has developed a version of its Diabetes Solution product for animal health purposes under the brand name GluCurve.
• The company is targeting organizations with global operations in order to work with their sales network to distribute its products.
• The company is working to obtain confirmation that its Diabetes Solution product will allow for services to be provided by physicians that will be reimbursed by health insurance companies.

Negatives

• The company has experienced net losses for each of the past three years, and it could experience additional losses and have difficulty achieving profitability in the future.
• The company could need to raise additional capital in the future, and if it is unable to secure adequate funds on terms acceptable to it, it could be unable to execute its business plan.
• The company's third-party distributor has generated limited sales for it to date.
• The company's inability to distinguish its Diabetes Solution and GluCurve products from other diabetes treatment compliance devices or solutions could limit the market acceptance of its products and its market share.
• The company has experienced long sales cycles as healthcare professionals (HCPs) have been, and could continue to be, slow to adopt new technologies on a widespread basis.
• The company could incur problems in manufacturing its products.
• The company could be unable to effectively manage and implement its growth strategies, which could have a material adverse effect on its business, financial condition, and results of operations.
• The company could be subject to breaches of its information technology systems, which could damage its reputation and customer relationships.
• The company could be subject to or otherwise affected by federal, provincial and state healthcare laws, including fraud and abuse and health information privacy and security laws, and it could face substantial penalties if it is unable to fully comply with such regulations.
• The company may be unable to maintain compliance with the OTCQB Standards for Continued Eligibility, which could cause its ordinary shares to be demoted from the OTCQB.
• The liquidity and trading volume of the company's ordinary shares could be low, and its ownership is concentrated.
• The company's share price has been, and could continue to be, volatile.
• The company could experience substantial dilution of its investment as a result of subsequent exercises of its outstanding options, outstanding warrants, future sales of its equity, or the future grant of equity by it.
• The company is organized under the laws of the Republic of Singapore and its shareholders may have more difficulty in protecting their interest than they would as shareholders of a corporation incorporated in the U.S., and it may have more difficulty attracting and retaining qualified Board members and executives.
• As a foreign private issuer, the company is exempt from a number of U.S. securities laws and rules promulgated thereunder and is permitted to publicly disclose less information than U.S. public companies must.
• The company may lose its foreign private issuer status in the future, which could result in significant additional costs and expenses.
• Singapore law may impede the company's takeover by a third-party.
• The company may still be treated as a U.S. corporation and taxed on its worldwide income.
• The company may be classified as a Passive Foreign Investment Company, which could result in adverse U.S. federal income tax consequences to U.S. Holders of its ordinary shares.
• As of December 31, 2023, the Company had promissory notes payable and related interest payable, totaling $10,425,000 in default.

Risks

• The company's recurring losses from operations and other factors have raised substantial doubt about its ability to continue as a going concern as of December 31, 2023.
• The company could need to raise additional capital in the future, and if it is unable to secure adequate funds on terms acceptable to it, it could be unable to execute its business plan.
• The company's success depends, in part, on securing and developing relationships with, and on the efforts of, third-party distributors to sell and distribute its Diabetes Solution and GluCurve products.
• The company's inability to distinguish its Diabetes Solution and GluCurve products from other diabetes treatment compliance devices or solutions could limit the market acceptance of its products and its market share.
• The company could incur problems in manufacturing its products.
• Product liability claims against the company could be costly and could harm its reputation.
• Rapidly changing standards and competing technologies could harm demand for the company's products, result in significant additional costs, and have a material adverse effect on its business, financial condition, and results of operations.
• The company could be unable to effectively manage and implement its growth strategies, which could have a material adverse effect on its business, financial condition, and results of operations.
• The company could be subject to breaches of its information technology systems, which could damage its reputation and customer relationships.
• Changes in government regulation or the inability to obtain or maintain necessary government approvals could have a material adverse effect on the company's business, financial condition, and results of operations.
• The company could be subject to or otherwise affected by federal, provincial and state healthcare laws, including fraud and abuse and health information privacy and security laws, and it could face substantial penalties if it is unable to fully comply with such regulations.
• Product sales or introductions could be delayed or canceled as a result of the regulatory requirements applicable to diabetes testing products, diabetes management systems, or both, for human use, which could delay the launch of the Diabetes Solution product, cause the company's sales or profitability to decline and have a material adverse effect on its business, financial condition, and results of operations.
• The company may be unable to maintain compliance with the OTCQB Standards for Continued Eligibility, which could cause its ordinary shares to be demoted from the OTCQB.
• The company's shares are classified as penny stocks and are covered by Section 15(g) of the Securities Exchange Act of 1934 (the Exchange Act), which imposes additional sales practice requirements on broker-dealers who sell the company's securities in this offering or in the aftermarket.
• The liquidity and trading volume of the company's ordinary shares could be low, and its ownership is concentrated.
• The company's share price has been, and could continue to be, volatile.
• The company could experience substantial dilution of its investment as a result of subsequent exercises of its outstanding options, outstanding warrants, future sales of its equity, or the future grant of equity by it.
• The company is organized under the laws of the Republic of Singapore and its shareholders may have more difficulty in protecting their interest than they would as shareholders of a corporation incorporated in the U.S., and it may have more difficulty attracting and retaining qualified Board members and executives.
• As a foreign private issuer, the company is exempt from a number of U.S. securities laws and rules promulgated thereunder and is permitted to publicly disclose less information than U.S. public companies must.
• The company may lose its foreign private issuer status in the future, which could result in significant additional costs and expenses.
• Singapore law may impede the company's takeover by a third-party.
• The company may still be treated as a U.S. corporation and taxed on its worldwide income.
• The company may be classified as a Passive Foreign Investment Company, which could result in adverse U.S. federal income tax consequences to U.S. Holders of its ordinary shares.
• If the patents that the company owns or licenses, or its other intellectual property rights, do not adequately protect its technologies, it could lose market share to its competitors and be unable to operate its business profitably.
• If third parties claim that the company infringes their intellectual property rights, it could incur liabilities and costs and have to redesign or discontinue selling certain products, which could have a material adverse effect on its business, financial condition, and results of operations.

Future Outlook

The company intends to improve its financial condition and ultimately improve its financial results by increasing revenues through introduction of its product into new markets, continuing to expand and develop its field sales force and distributor relationships both domestically and internationally, forming strategic arrangements within the health & wellness and medical industries, educating medical professionals and patients as to the benefits of its diabetes management services, and reducing expenses.

Industry Context

The document highlights the increasing prevalence of diabetes and the associated healthcare costs, emphasizing the need for effective diabetes management solutions. The company positions its Diabetes Solution and GluCurve products as tools to address key challenges in diabetes care, such as patient non-adherence, unreliable data, data overload, clinical inertia, and insulin under-prescription. The document also acknowledges competition from other companies in the diabetes compliance device and monitoring system market, including Livongo, Glooko, WellDoc, Medtronic, iGlucose, and Microsoft HealthVault.

Comparison to Industry Standards

• The document mentions competitors like Livongo, Glooko, WellDoc, Medtronic, iGlucose, and Microsoft HealthVault, but does not provide a detailed comparison of ALR Technologies' results against specific industry benchmarks.
• The document references the Diabetes Control and Complication Trial (DCCT) to outline management practices, but does not compare ALR Technologies' results to the DCCT's findings.
• The document cites a Cleveland Clinic study on clinical inertia, but does not compare ALR Technologies' performance in addressing clinical inertia to the study's findings.
• The document mentions the AlphaTRAK BGM system as a competitor in the animal health market, but does not provide a detailed comparison of GluCurve Pet CGM's performance against AlphaTRAK.

Legal Proceedings

• The company has had three judgments against it relating to overdue promissory notes and accrued interest, and a fourth creditor has demanded repayment of an overdue promissory note and accrued interest.
• On January 17, 2024, a further default judgment was entered against the Company in regards to one of the above noted judgments totaling $255,000, consisting of the principal amount of $125,000 and accrued interest of $130,000.

Related Party Transactions

• The company has significant related party transactions, including lines of credit, promissory notes, and a loan payable with the CEO, VP, and their relatives.
• The company incurred interest expense of $328,000 on $3,092,000 of promissory notes due to relatives of Sidney Chan.
• The company incurred interest expense of $160,000 and borrowing costs (recorded as interest expense) on loan payable to a company controlled by Christine Kan and her immediate family members.
• The company incurred interest expense of $1,644,000 on $14,211,000 of amounts borrowed and outstanding on the lines of credit payable to Sidney Chan and Christine Kan.
• The company owed accrued interest on promissory notes to relatives of Sidney Chan of $1,848,000.
• The company owed accrued interest on lines of credit payable to Sidney Chan and Christine Kan of $3,745,000.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial difficulties and potential need for additional capital.
• Creditors face the risk of non-payment due to the company's financial difficulties and potential inability to repay debts.
• Employees face uncertainty about job security due to the company's financial difficulties and potential need to cease operations.
• Customers and distributors face uncertainty about the company's ability to continue providing products and services due to its financial difficulties.

Next Steps

• The company is evaluating vendors to launch the second generation CGM Hardware for the GluCurve Pet CGM.
• The company is evaluating CGM systems to bundle with its Diabetes Solution product for human health.
• The company expects to secure CGM system supply during 2024, subsequent to which it can initiate a clinical trial and prepare for a subsequent clearance from regulatory authorities to sell in key target countries for roll out.
• The company is targeting to offer its Diabetes Solution product bundled with CGM with pricing to compete with the standalone BGM offerings.
• The company will seek to obtain creditors consents to delay repayment of these loans until it is able to replace these financings with funds generated by operations, replacement debt, or from equity financings through private placements or the exercise of options and warrants.

Key Dates

Keywords

financials, going concern, diabetes solution, glucurve, annual report, alr technologies, financial statements, otcqb, shareholders, singapore